Close Menu

NEW YORK – Merck yesterday announced positive progression-free survival data for its anti-PD-1 therapy pembrolizumab (Keytruda) combined with chemotherapy as a first-line treatment for patients with metastatic triple-negative breast cancer.

According to results from the Phase III KEYNOTE-355 trial comparing pembrolizumab in combination with chemotherapy against chemotherapy and placebo, patients treated with the pembrolizumab combination experienced a significant improvement in progression-free survival, translating to a reduced risk of disease progression or death.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.